1. Describe bilirubin metabolism 2. Enumerate the etiology and pathogenesis of jaundice 3. Distinguish between direct and indirect hyperbilirubinemia.
Reading File
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Loading Image
Loading Image
I now have comprehensive content from multiple authoritative textbooks. Let me compile the full, detailed answer.
Bilirubin Metabolism, Jaundice, and Hyperbilirubinemia
1. Bilirubin Metabolism
Source of Bilirubin
Bilirubin is a tetrapyrrole compound and the end product of heme catabolism. A healthy adult produces approximately 4 mg/kg/day (~250-300 mg/day in a 70-kg person).
- 70-80% derives from degradation of hemoglobin released from senescent erythrocytes (destroyed in the spleen, bone marrow, and liver Kupffer cells)
- 20-30% comes from breakdown of other heme-containing proteins (e.g., cytochrome oxidases, catalase) in hepatocytes, as well as ineffective erythropoiesis
Step 1: Heme to Bilirubin (in Peripheral Tissues)
The conversion of heme to bilirubin occurs in two sequential enzymatic steps:
- Heme oxygenase (HO) opens the porphyrin ring of heme, releasing iron (Fe³+), carbon monoxide (CO), and producing biliverdin (a water-soluble green pigment). Two isoforms exist: HO-1 (inducible, ubiquitous) and HO-2 (constitutive, found in hepatocytes). The reaction requires NADPH and O₂.
- Biliverdin reductase (BVRA) then reduces biliverdin IXα to bilirubin IXα (the predominant form), using NADPH.
The resulting bilirubin is highly hydrophobic and water-insoluble in its unconjugated (free) form.
Step 2: Transport in Blood
Unconjugated bilirubin circulates in plasma tightly and non-covalently bound to albumin (due to its insolubility in aqueous solution). It cannot be filtered at the glomerulus and therefore does not appear in urine.
Step 3: Hepatic Handling - Four Key Steps
(a) Hepatocellular Uptake
Albumin-bound bilirubin passes through sinusoidal endothelial fenestrae to reach the hepatocyte surface. Free bilirubin is taken up via a proposed bilirubin transporter (BT) and possibly via organic anion transporting polypeptides (OATPs), by both facilitated and diffusional mechanisms. This step is competitively inhibited by certain drugs (rifampin, cyclosporine A), which inhibit OATP1B1.
(b) Intracellular Binding
Within the hepatocyte, unconjugated bilirubin binds to cytosolic proteins - primarily glutathione-S-transferases (GSTs), formerly called ligandins, and fatty acid binding proteins. These keep bilirubin in solution and transport it to the endoplasmic reticulum (ER).
(c) Conjugation
In the smooth ER, bilirubin is conjugated with glucuronic acid by bilirubin UDP-glucuronosyltransferase (UGT1A1), encoded by the UGT1A1 gene. Each bilirubin molecule reacts with two UDP-glucuronic acid (UDPGA) molecules to form bilirubin diglucuronide (and monoglucuronide). This conjugation:
- Disrupts internal hydrogen bonds, making bilirubin highly water-soluble
- Is obligatory for biliary excretion
The UGT1 gene complex on chromosome 2 encodes multiple isoforms via alternative first exons (A1-A13), with shared common exons 2-5. Mutations in exon A1 affect only UGT1A1 (bilirubin conjugation), while mutations in common exons (2-5) affect all UGT1 isoforms.
(d) Biliary Excretion
Bilirubin mono- and diglucuronides are excreted across the canalicular membrane into bile via multidrug resistance-associated protein 2 (MRP2, ABCC2), an ATP-dependent active transporter. A portion of glucuronides is also exported back into the portal circulation by MRP3 (ABCC3) on the sinusoidal membrane and undergoes re-uptake by OATP1B1 and OATP1B3 (mutations in these transporters cause Rotor syndrome).
Step 4: Intestinal Metabolism and Enterohepatic Circulation
- Conjugated bilirubin passes down the gut without reabsorption by intestinal mucosa (which is relatively impermeable to it)
- Intestinal bacteria convert bilirubin to a series of colorless compounds called urobilinogens
- Most urobilinogen is excreted in feces (as stercobilin, giving stool its brown color)
- A small fraction is reabsorbed into the portal circulation and undergoes enterohepatic cycling - taken up again by the liver and re-excreted in bile; a small amount escapes hepatic extraction and enters systemic circulation to be excreted in urine as urobilinogen
Renal Excretion
- Unconjugated bilirubin is NOT excreted in urine - too tightly bound to albumin for glomerular filtration; no tubular secretion mechanism
- Conjugated bilirubin (water-soluble) is readily filtered at the glomerulus, hence bilirubinuria occurs in conjugated (direct) hyperbilirubinemia
2. Etiology and Pathogenesis of Jaundice
Jaundice (icterus) is the yellowish discoloration of skin, sclera, and mucous membranes from bilirubin deposition, clinically apparent when serum bilirubin exceeds ~2-3 mg/dL (normal: 0.2-1.0 mg/dL). It results from an imbalance between bilirubin production and hepatobiliary clearance.
Jaundice is classified by mechanism and site of the defect:
A. PRE-HEPATIC (Unconjugated Hyperbilirubinemia - Increased Production)
Mechanism: Excess bilirubin production overwhelms the liver's conjugating capacity.
| Cause | Pathogenesis |
|---|---|
| Hemolysis (sickle cell, G6PD deficiency, hereditary spherocytosis, autoimmune hemolytic anemia, malaria) | Accelerated RBC destruction → increased heme catabolism → increased unconjugated bilirubin. Bilirubin rarely exceeds 4-5 mg/dL with isolated hemolysis (normal liver). Higher values suggest concurrent hepatic dysfunction. Prolonged hemolysis may cause pigment (bilirubin) gallstones. |
| Ineffective erythropoiesis (thalassemia major, megaloblastic anemia, sideroblastic anemia, lead poisoning, porphyria) | Destruction of developing erythroid cells in the marrow before they reach circulation; can account for up to 70% of bilirubin production in severe cases. |
| Resorption of large hematomas / massive tissue infarctions | Degradation of extravasated hemoglobin → transient unconjugated hyperbilirubinemia |
| Massive blood transfusion | Increased fragility of stored erythrocytes → excessive hemoglobin release |
B. HEPATIC (Intrinsic Liver Disease)
Mechanism: Defects in hepatocellular uptake, conjugation, or intrahepatic transport. Can cause mixed or isolated unconjugated/conjugated hyperbilirubinemia.
i. Decreased Hepatic Uptake
- Gilbert syndrome (partial): Reduced uptake contributes to unconjugated hyperbilirubinemia
- Drugs: Rifampin, novobiocin, flavaspidic acid, cyclosporine, cholecystographic contrast agents inhibit OATP1B1 and bilirubin uptake
ii. Impaired Conjugation (Unconjugated Hyperbilirubinemia)
- Physiologic neonatal jaundice: UGT1A1 activity is low at birth; immature intestinal flora lead to enterohepatic circulation of unconjugated bilirubin. Usually resolves by 1-2 weeks.
- Gilbert syndrome: Mild reduction in UGT1A1 activity (due to promoter mutation - insertion in TATA box of UGT1A1 gene); unconjugated bilirubin typically <4 mg/dL; exacerbated by fasting, illness, exercise. Benign.
- Crigler-Najjar Syndrome Type I: Complete absence of UGT1A1 activity; bilirubin 20-45 mg/dL; risk of kernicterus; fatal without treatment (liver transplant).
- Crigler-Najjar Syndrome Type II: Severe reduction (not absence) of UGT1A1; bilirubin 6-25 mg/dL; responds to phenobarbital (induces residual enzyme); kernicterus rare.
- Breast milk jaundice: Prolonged mild unconjugated hyperbilirubinemia in neonates; possibly due to inhibitors of UGT1A1 in breast milk.
iii. Intrahepatic Excretion Defects (Conjugated/Direct Hyperbilirubinemia)
- Dubin-Johnson syndrome: Mutation in MRP2 (ABCC2); impaired canalicular export of conjugated bilirubin. Mild conjugated hyperbilirubinemia, black liver pigment on biopsy, elevated coproporphyrin isomer I in urine. Benign.
- Rotor syndrome: Mutations in both OATP1B1 and OATP1B3; impaired sinusoidal re-uptake of refluxed conjugated bilirubin. Mild conjugated hyperbilirubinemia. Benign.
- Benign recurrent intrahepatic cholestasis (BRIC): Mutations in FIC1 (ATP8B1) or BSEP (ABCB11); recurrent episodes of cholestasis.
- Progressive familial intrahepatic cholestasis (PFIC): Same gene defects as BRIC but more severe; can progress to liver failure.
iv. Hepatocellular Disease (Mixed/Conjugated Hyperbilirubinemia)
- Acute viral hepatitis (HAV, HBV, HCV, HDV, HEV): Hepatocellular necrosis and inflammation → impaired all steps of bilirubin metabolism. Preceded by prodrome of malaise, anorexia, myalgias.
- Drug-induced liver injury (DILI): Acetaminophen (dose-dependent), idiosyncratic drug reactions
- Alcoholic hepatitis: Multifactorial liver injury
- Ischemic hepatitis: Hypotension, hypoxia, hyperthermia, Budd-Chiari syndrome
- Wilson disease: Inherited disorder of copper metabolism; may mimic acute viral hepatitis; hemolytic component adds unconjugated bilirubin
- Chronic liver disease/Cirrhosis: Viral hepatitis (B, C), NAFLD/NASH, alcoholic cirrhosis, hemochromatosis, alpha-1 antitrypsin deficiency, autoimmune hepatitis - jaundice generally signals advanced disease
- Drugs producing intrahepatic cholestasis: Estrogens (down-regulate NTCP, inhibit BSEP and MRP2), anabolic steroids, total parenteral nutrition
- Sepsis-associated cholestasis: Cytokine-mediated down-regulation of NTCP, MRP2, and BSEP
- Paraneoplastic (Stauffer syndrome): Intrahepatic cholestasis without hepatic infiltration, especially renal cell carcinoma and lymphoma; resolves with tumor treatment
C. POST-HEPATIC (Obstructive/Cholestatic) - Conjugated Hyperbilirubinemia
Mechanism: Obstruction to bile flow → backflow of conjugated bilirubin into systemic circulation.
| Cause | Examples |
|---|---|
| Intraluminal obstruction | Choledocholithiasis (common bile duct stones) |
| Mural obstruction | Cholangiocarcinoma, primary sclerosing cholangitis (PSC), biliary strictures, biliary atresia (neonates) |
| Extramural compression | Carcinoma of head of pancreas, ampullary carcinoma, pancreatic pseudocyst, lymph nodes at porta hepatis, Mirizzi syndrome |
| Ampullary pathology | Ampullary carcinoma |
Features of obstructive jaundice: Dark urine (bilirubinuria), pale stools (absent stercobilin), pruritus (bile salt deposition in skin), steatorrhea (fat malabsorption due to absent bile), elevated alkaline phosphatase and GGT predominating over transaminases.
3. Direct vs. Indirect Hyperbilirubinemia
This distinction is based on the van den Bergh reaction (diazo reaction):
- Direct-reacting bilirubin = conjugated bilirubin (water-soluble; reacts directly without alcohol addition)
- Indirect-reacting bilirubin = unconjugated bilirubin (lipid-soluble; requires alcohol addition to react)
- Total bilirubin = direct + indirect
| Feature | Indirect (Unconjugated) Hyperbilirubinemia | Direct (Conjugated) Hyperbilirubinemia |
|---|---|---|
| Chemical form | Free bilirubin (unconjugated) | Bilirubin glucuronide (conjugated) |
| Water solubility | Insoluble (lipid-soluble) | Water-soluble |
| Albumin binding | Tightly bound to albumin | Loosely bound; can dissociate |
| Urine bilirubin (bilirubinuria) | Absent (cannot be filtered) | Present (filtered at glomerulus) |
| Urine color | Normal | Dark ("tea-colored" urine) |
| Stool color | Normal | Pale (acholic stools if obstructive) |
| Site of defect | Pre-hepatic or hepatic (uptake/conjugation defect) | Hepatic (excretion defect) or post-hepatic (obstruction) |
| Blood-brain barrier crossing | YES - lipid-soluble; can cause kernicterus | No |
| Kernicterus risk | Yes (especially neonates) | No |
| Causes | Hemolysis, ineffective erythropoiesis, Gilbert syndrome, Crigler-Najjar, physiologic neonatal jaundice, impaired hepatic uptake (drugs) | Dubin-Johnson, Rotor syndrome, hepatocellular disease (hepatitis, cirrhosis), intrahepatic cholestasis, extrahepatic biliary obstruction |
| Delta bilirubin | Not present | In prolonged conjugated hyperbilirubinemia, bilirubin covalently binds to albumin ("delta bilirubin") - prolonged half-life, not in urine |
| Serum alkaline phosphatase | Normal | Elevated (especially in cholestasis/obstruction) |
| Urine urobilinogen | Elevated (in hemolysis) | Low/absent (in obstruction; no bilirubin reaches gut) |
Key Clinical Distinction
- If direct bilirubin >50% of total: implies hepatocellular disease or biliary obstruction - requires further workup (liver enzymes, imaging)
- If indirect bilirubin predominates: think pre-hepatic (hemolysis) or impaired conjugation
- The direct fraction as measured by clinical labs is typically ≤15% of total in pure hemolysis (Harrison's, Chap. 349)
- Conjugated bilirubin can be filtered and excreted in urine; unconjugated cannot - hence the clinical pearl: "acholuric jaundice" (jaundice without bilirubinuria) = unconjugated hyperbilirubinemia (e.g., hemolysis)
Sources: Harrison's Principles of Internal Medicine 22E, Chap. 349; Sleisenger & Fordtran's Gastrointestinal and Liver Disease; Ganong's Review of Medical Physiology 26E; Schwartz's Principles of Surgery 11E
This is a shared conversation. Sign in to Orris to start your own chat.